Ark Therapeutics Ltd.
This article was originally published in Start Up
Executive Summary
The founders of MediGene AG and Eurogene Ltd. have formed Ark Therapeutics to combat cardiovascular diseases such as de novo stenosis through the delivery of VEGF by gene therapy. The new company possesses the pieces that it hopes will allow it to go from identifying genes to producing medicines; functional genomics, gene vector and animal research capabilities, biology, chemistry, gene delivery development and clinical expertise.